Summary
The regulation of cellular LDL metabolism by hypertriglyceridemic LDL was tested before and after treatment with acipimox, a nicotinic acid derivative, in 11 type IV hyperlipidemic patients. Large, less dense LDL particles were found in plasma after acipimox treatment. HDL subfractions were only slightly modified, with an increase of dense, cholesteryl ester-enriched and triglyceride-poor HDL3 particles. The LDL (B, E) receptor activity in human skin fibroblasts of LDL isolated before and after treatment was also evaluated. Hypertriglyceridemic LDL proved rather inefficient in regulating receptor activity, with a close to 30% lower capacity than normal LDL to inhibit receptor-mediated uptake and degradation of125I-LDL. This abnormality was fully corrected after acipimox. The reported findings indicate that acipimox treatment in type IV patients can normalize the defective interaction of hypertriglyceridemic LDL with the LDL (B, E) receptor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Weimer M, Van Eys J (1986) Nicotinic acid: nutrient-cofactor drug. (Clinical pharmacology series, vol 1) Marcel Dekker, New York
Canner PL, Berge KG, Wenger MK, Stamler J, Friedman L, Prineas RJ, Friedewald W (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1245–1255
Sirtori CR, Gianfranceschi G, Sirtori M, Bernini F, Deschovich GC, Montaguti U, Fuccella LM, Musatti L (1981) Reduced triglyeridemia and increased high density lipoprotein cholesterol after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 38: 267–271
Crepaldi G, Avogaro P, Descovich GC, Di Perri T, Postiglione A, Sirtori CR, Strano A, Ventura S, Musatti L (1988) Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis 70: 115–121
Stuyt PMJ, Stalenhoef AFH, Demacker PNM, Van't Laar A (1985) A comparative study on the effects of acipimox and clofibrate in type III and IV hyperlipoproteinemia. Atherosclerosis 55: 51–62
Fuccella LM, Goldaniga G, Lovisolo PP, Maggi E, Musatti L, Mandelli V, Sirtori CR (1980) Inhibition of lipolysis by nicotinic acid and acipimox. Clin Pharmacol Ther 28: 790–795
Stirling C, McAleer M, Reckless JPD, Campbell RR, Mundy D, Betteridge DJ, Foster V (1985) Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosae. Clin Sci 68: 83–88
Kleinman Y, Eisenberg S, Oschry Y, Gavish D, Stein O, Stein Y (1985) Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. J Clin Invest 75: 1796–1803
Aviram M, Bierman EL, Chait A (1988) Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 263: 116–122
Mancini M, Farinaro E, Postiglione A, Rubba P, Strazzullo P (1980) Role of diet in atherosclerosis. Atheroscler Rev 7: 157–167
Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345–1353
McFarlane AS (1958) Efficient trace labelling of proteins with iodine. Nature 182: 53
Bilheimer DW, Eisenberg S, Levy RI (1972) The metabolism of very low density lipoprotein proteins: I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 260: 212–221
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Brown MS, Goldstein JL (1975) Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 6: 307–316
Musatti L, Maggi E, Moro E, Valzelli G, Tamassia V (1981) Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent. J Int Med Res 9: 381–386
Kleinman Y, Oschry Y, Eisenberg S (1987) Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy. Eur J Clin Invest 17: 538–543
Carlson LA, Olsson AG, Orö L, Rössner S, Walldius G (1974) Effects of hypolipidemic regimes on serum lipoproteins. In: Schettler G, Weizel A (eds) Atherosclerosis, vol III. Springer, Berlin Heidelberg New York, pp 768–781
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Franceschini, G., Bernini, F., Michelagnoli, S. et al. Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia. Eur J Clin Pharmacol 40, S45–S48 (1991). https://doi.org/10.1007/BF01409408
Issue Date:
DOI: https://doi.org/10.1007/BF01409408